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Summary.-Intrapleural growth of transplanted rat tumours was prevented or
retarded by intrapleural administration of double-stranded RNA. A similar sup-
pression of growth was achieved with peritoneal tumours by the intraperitoneal
injection of the compound. These studies indicate the possible potential of this form
of treatment of thoracic and peritoneal tumours for clinical application in the treat-
ment of mesothelioma.
DIRECT contact between microbial
adjuvants and tumour cells may often
produce a more marked suppression of
tumour growth than that achieved by
general immunostimulation following their
systemic administration. For example,
with Corynebacterium parvum, growth of
carcinomata in the mouse (Likhite and
Halpern, 1973) and rat sarcomata (Pimm
and Hopper, 1975a) is restricted when
cells are injected in admixture with killed
organisms, and intralesional injections
may lead to regression of a transplanted
hamster melanoma (Paslin, Dimitrov and
Heaton, 1974). In addition, growth of
syngeneically transplanted rat (Baldwin
and Pimm, 1971) and mouse (Bartlett,
Zbar and Rapp, 1972) sarcomata is
suppressed when tumour cells are injected
in admixture with Bacillus Calmette-
C(terin (BCG) organisms. BCG contact
with tumour cells similarly suppresses
growth of other tumours, including rat
and guinea-pig hepatomata (Zbar, Bern-
stein and Rapp, 1971; Hopper, Pimm and
Baldwin, 1975a), and a mammary car-
cinoma and epithelioma in the rat
(Hopper et al., 1975a; Baldwin and
Pimm. 1973a).
In addition to bacterial preparations,
douible stranded RNA (ds-RNA) of viral
origin is also tumour suppressive when
injected subcutaneously in admixture
with transplanted rat tumours. Thus,
growth of rat sarcomata, a hepatoma, a
mammary carcinoma and an epithelioma
is prevented or retarded when cells are
injected subcutaneously together with
ds-RNA (Pimm, Embleton and Baldwin,
1975) and intralesional injections may
restrict growth of subcutaneous trans-
plants of mouse sarcomata and lympho-
mata (Heyes, Catherall and Harnden,
1974; Parr, Wheeler and Alexander,
1973).
Clinically, this type of adjuvant con-
tact suppression has so far been limited to
the treatment of surface tumours, partic-
ularly melanomata with BCG, where
intralesional injections may cause
regressions (Morton et al., ]970; Pinsky,
Hirshaut and Oettgen, 1973). Experi-
mentally, this type of treatment can also
be effective with tumours at other
anatomical sites. For example, growth of
pulmonary tumour deposits (Baldwin and
Pimm, 1973b) and pulmonary metastases
(Baldwin and Pimm, 1973a, 1974) may be
restricted by the introduction of BCG
organisms into lung tissue by intravenous
injection, and growth of intrapleural and
intraperitoneal tumour is controlled byTREATMENT OF TRANSPLANTED RAT TUMOURS. II
injection of BC'G inito these body cavities
(Pimm and Baldwin, 1975).
More defined preparations, free of
these side-effects known to be produced by
mycobacterial materials (Pinsky et al.,
1973; Hunt et al., 1973) are clearly
desirable for clinical application of this
treatment. Sin-ce intrapleurally or intra-
peritoneally injected BCG will suppress
tumours at these sites (Pimm and
Baldwin, 1975), and ds-RNA injected
locally Will suppress subcutaneous
tumours (Pimm et al., 1975), the studies to
be described here were carried out to
assess the influence of intrapleurally and
intraperitoneally inijected ds-RNA on
tumours at these sites. These tests were
carried out as part of a programme for
designing new techniques for the treat-
ment of malignant mesothelioma in man,
where preliminary clinical results (Elmes,
personial communication) suggest that
intrapleurally inijected BCG may have an
application for treatment of this disease.
The results of the present experiments are
compared with previous reports on the
application of BCG to the treatment of
experimental pleural tumours in the rat
(Pimm and Baldwini, 1975).
MATERIALS AND METHODS
Tumon,urs.-Tumours were induced with
chemical carcinogens or arose without delib-
eratre induction in rats of an inbred Wistar
strain and have been described previously
(Pimm et al., 1975). Single cell suspensions
were prepared as previously described (Pimm
et al., 1975).
Double stranded RNA (ds-RNA).-Fungal
virus ds-RNA (BRL 5907) was supplied by
Beecham Research Laboratories, Betchworth,
Surrey and prepared for injection as described
previously (Pimm et al., 1975).
Transplantation of tumours. Pleural and
peritoneal tumour growths wNere produced
by injections of single cell suspensions as
described previously (Pimm et al., 1975).
Methods of treatment. Animals receiving
intrapleural or intraperitoneal injections of
tumour cells were treated by injection of
ds-RNA into the same site. When treatment
was given at, the same time as tumour injec-
tion, cells and ds-RNA wNere injected in
admixture.
Assessment of tu?mour gro?th.- Rats were
killed individually when exhibit,ing respira-
t,ory distress caused by the development of
pleural tumour gro-wths. Survivals were
expressed in days, with respect to initial
tumour cell injection. Statistical signifi-
cance of the difference between survival of
treated and control rats was assessed bythe
Wilcoxon non-parametric rank test.
RESULTS
Treatment of intrapleural yrowths
Tests on the treatment of intrapleural
growth of Mc induced sarcomata with
ds-RNA are summarized in Table I.
With sarcoma Mc7 growth of a challenge
with I x 106 tumour cells was not
completely suppressed by an intrapleural
injection of 100 ,tg of ds-RNA, although
the survival of treated rats (16-44 days)
was increased when compared with that of
controls (12-24 days). Three further
tests with sarcomata Mc7 were carried out,
treating a challenge inoculum of 2 x 106
tumour cells with 250 ,ag of ds-RNA. In
each case, this resulted in complete
suppression of tumour growth, as judged
by the absence of macroscopically visible
tumours when the experiments were
terminated (Day 30-55). In comparison,
all but 2 of 15 control rats developed
intrapleural tumours, this necessitating
killing of these animals between Days 15
and 40. In a further test with sarcoma
Mc7 (Experiment 5), the effect of pre-
treating rats with ds-RNA a or 7 days
before tumour challenge was compared
with the response obtained when tumour
cells were injected admixed with ds-RNA.
Treatment at the same time as tumour
challenge again completely suppressed
tumour growth whereas the pretreatment
schedule had no effect.
In tests with sarcoma, Mc57, growth of
tumour cells injected intrapleurally in
admixture with ds-RNA (250 ,ug) was
completely arrested (Experiment 7) or
inhibited leading to prolonged survival of
treated rats (Experiments 6 and 8). In
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TABLE I.-Double-stranded RNA Treatment of Intrapleurally Injected Rat Sarcomata
Expt
1
2
3
4
5
6
7
8
Tumour
Mc7
Mc7
Mc7
Mc7
Mc7
Mc57
Mc57
Mc57
No. of
cells
1 X 106
1 X 106
2 x 106
2 x 106
2 x 106
2 x 106
2 x 106
2 x 106
5 x 105
5 x 105
5 x 105
5 x 105
1 X 106
1 X 106
2 x 106
2 x 106
1 X 106
1 X 106
1 X 106
1 X 106
Intrapleural
treatment
_ A
,ug ds-RNA
100
250
250
250
250
250
250
250
250
250
250
250
Day*
0
0
0
0
-5
-7
0
0
0
0
2
4
* With respect to tumour cell injection.
TABLE II.-Intrapleural Gro
Expt Tumour
1 Mammary
carcinoma AAF57
2 AAF57
3 AAF57
4 Sarcoma Sp24
5 Sarcoma Sp24
6 Sarcoma Sp24
wth of
Survival
(days)
16, 16, 33, 44, 44
12, 14, 14, 14, 14, 24
Terminated Day 47
31, 31, 33, 40, Terminated Day 47
Terminated Day 55
17, 17, 38, 39, Terminated Day 55
Terminated Day 30
15, 17, 17, 17, 20
13, 14, 16, 16, Terminated Day 47
14, 14, 16, 16, 17, 17
Terminated Day 47
13, 16, 16, 16, 17 Terminated Day 47
14, 21, 27, 28
14, 14, 14, 14, 14
Terminated Day 43
13, 13, 17, 25
49, 49, Terminated Day 56
49, 49, Terminated Day 56
36, 49, Terminated Day 56
22, 22, 22, 38, 38
Tumour Cells Injected in Admixture with
Double-stranded RNA
Mixed inoculum
A-
No. of
cells
5 x 102
5 x 102
1 x 103
1 x 103
2 x 104
2 x 104
l x 104
1 X 104
a x 104
5 x 104
5 x 104
5 x 104
jig ds-RNA
250
250
250
250
250
250
* With respect to tumouir cell injection.
Experiment 8, treatment was delayed
until 2 or 4 days after tumour challenge
but even so, tumour growth was com-
pletely suppressed or the survival of
treated rats was prolonged.
In comparison with theeffects observed
following intrapleural injection of cells of
the immunogenic sarcomata (Mc7 and
Mc57) in admixture with ds-RNA, this
treatment did not induce complete sup-
pression of 2 weakly immunogenic
Survival
[(days*)
26, 26, 26, 26, 27
20, 20, 20, 21
21, 26, 26, 26
19, 19, 20, 20
21, 21, 23, 28, 28
19, 21, 21, 21, 23
26, 28, 28
19, 23, 23
23, 30, 32, 33
21, 23, 23, 23
17, 17, 26, 26, 26
17, 17, 19, 26
p
001
0 025
0-08
0 -05
0-025
0 40
tumours, mammary carcinoma AAF57
and sarcoma Sp24 (Table II). For
example, injection of either 5 x 102 or
1 X 103 mammary carcinoma AAF57
cells admixed with ds-RNA (250,ug)
resulted in progressively growing tumours
in all of the recipients. However, the
growth oftumours was affected by contact
with ds-RNA and this is reflected in the
small but significant increase in survival
times. A similar response was obtained in
No. of rats
with
pleural
tumours
5/5
6/6
0/7
4/5
0/5
4/5
0/5
5/5
5/5
6/6
0/6
5/6
4/4
5/5
0/4
4/4
2/4
2/3
2/4
5/5
No. of rats
with
pleural
tumours
5/5
4/4
4/4
4/4
5/5
5/5
3/3
3/3
4/4
4/4
5/5
4/4
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TABLE III.-Intraperitoneal Growth of Tumour Cells Injected
with Double-stranded RNA
Mixed inoculum
A
Expt Tumour
1 Sarcoma Mc7 2
2
2 Sarcoma Mc7 2
2
3 Sarcoma Mc57 2
2
4 Sarcoma Sp24 5
5
5 Sarcoma Sp24 2
2
6 Mammary 1
carcinoma AAF57 1
7 Mammary 1
carcinoma AAF57 1
No. of
cells
X 106
X 106
X 106
X 106
x 106
x 106
X 104
X 104
x 104
X 104
X 104
X 104
X 104
X 104
,ug ds-RNA
250
250
250
250
250
250
250
* With respect to tumour cell injection.
Survival
(days*)
Terminated Day 57
25, 29, 32, 32, 47
Terminated Day 30
14, 14, 14, 14, 14
Terminated Day 45
20, 20, 20, 20
34, 34, 35, 35, 35
21, 21, 25, 25, 25
34, 34, 34, 48, 49
27, 27, 27, 27
23, 23, 23, 27, 27
23, 23, 23, 27, 27
20, 20, 20, 20, 20
20, 20, 20, 20, 20
in Admixture
No. of rats
with
peritoneal
P tumours
- 0/4
- 5/5
0/5
5/5
0/4
4/4
0 004 5/5
5/5
0 004 5/5 _ 5/5
5/5
5/5
-- 5/5
5/5
tests with sarcoma Sp24 where progressive
tumours were observed in all treated rats
but in 2 of the 3 tests there was a signi-
ficant increase in survival.
Treatment of intraperitoneal tumours
Further tests were carried out to assess
the response to tumour cells injected
intraperitoneally in admixture with ds-
RNA and the results are compatible with
those obtained employing intrapleural
tumour challenge (Table III). Thus, with
both sarcoma Mc7 and Mc57 growth from
a challenge inoculum of 2 x 106 tumour
cells was totally suppressed by the
presence of ds-RNA (250 ,ug). In com-
parison, challenges with sarcoma Sp24
(2-5 x 104 cells) and mammary carcinoma
AAF57 (1 x 104 cells) were not suppressed
when tumour cells were injected in ad-
mixture with ds-RNA although treatment
did result in a significant increase in
survival of sarcoma Sp24 treated rats.
DISCUSSION
It has previously been reported that
the growth ofsubcutaneously transplanted
rat tumours can be prevented or retarded
by injecting tumour cells in admixture
with ds-RNA (Pimm et al., 1975). The
present studies extend these observations,
demonstrating that introduction of ds-
RNA into the pleural and peritoneal
cavities may control tumour growth at
these sites and are comparable with
earlier studies indicating that growth of
these tumours can be controlled also by
contacting them with BCG (Pimm and
Baldwin, 1975; Baldwin and Pimm, 1971;
Hopper et al., 1975a). Here, too, growth
of subcutaneous inocula of Mc induced
sarcomata, mammary carcinoma AAF57
and sarcoma Sp24 can be prevented by
admixture with BCG but efficient sup-
pression ofintrapleural and intraperitoneal
growths is achieved only with the chemic-
ally induced sarcomata. There are
differences in the responses to these 2
reagents, however, since whilst both
ds-RNA and BCG exhibited a degree of
inhibitory reactivity when given several
days after tumour challenge, only BCG
was effective prophylactically when given
before the tumour cells.
The ds-RNA preparations used in the
present studies are cytotoxic in vitro for
rat tumour cells (Pimm et al., 1975) and
this toxic response must contribute to
some extent in the suppression of tumour
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growth at intraperitoneal and intrapleural
sites. The finding that tumours vary
quite markedly in their in vivo response to
ds-RNA, this being correlated to some
extent with the known immunogenicity of
susceptible tumours suggests, however,
that host responses are also involved. In
this context it is relevant that the
susceptibility of tumours to suppression
in vivo by contact with ds-RNA closely
approximates to their responses to BCG
mediated suppression and in this case
there is good evidence for an involvement
of macrophages. This is emphasized by
tests showing that macrophage depletion
of rats by silica treatment abrogates BCG
mediated suppression of tumour growth,
although immunosuppression by whole
body irradiation has no effect on this
response (Hopper et al., 1975b; Pimm and
Hopper, 1975b). Similar tests with ds-
RNA are in progress in order to evaluate
the role of host factors in its tumour
suppressive action.
Whatever is the mode of action of
ds-RNA, the present studies as well as the
previous findings on the treatment of
subcutaneous tumours (Pimm et al., 1.975)
indicate that tumour suppression by
locally administered agents is not
restricted to bacterial adjuvants such as
Corynebacteria and Mycobacteria, but can
be achieved with more simple, water
soluble agents. The double stranded
RNA (BRL 5907) used throughout these
studies is of natural viral origin but
synthetic polynucleotides such as
polyinosinic-polycytidylic acid (poly I-C)
warrant investigation. Furthermore, in
considering clinical application of these
reagents, the toxicity of ds-RNA needs to
be compared with that of bacterial
adjuvants such as BCG. In this context,
chemical modification of ds-RNA to
reduce toxicity and increase tumour
inhibitory activity is more feasible than
with bacterial adjuvants where the active
factor is ill defined. For example, Heyes
et al. (1974) have reported that a poly-
quaternary ammonium complex of ds-
RNA is more effective than the parent
compound in suppressing growth of a
mouse lymphoma. This compound is
now being tested against the tumours
described in this paper and, in addition,
the feasibility ofusing ds-RNA compounds
for the treatment of tumours at other
anatomical sites, including pulmonary
metastases, is being explored.
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